CD47 and neoplasm: The anti-tumor efficacy of CAR-Ms combined with oAd-CD47 (C + o) treatment was evaluated in vivo using two tumor-bearing mice models: CT26 colon cancer subcutaneous tumor model and the B16 melanoma subcutaneous tumor model.